Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
The latest news, research, and perspectives in acute lymphoblastic leukemia (ALL). The most common type of leukemia in children, ALL develops when bone marrow produces a large number of immature lymphoblasts that grow quickly and replace normal cells in the bone marrow.
Advertisement
Melissa BadamoAcute Lymphoblastic Leukemia | February 23, 2024
53.8% of patients treated with blinatumomab achieved MRD negativity within a median of 3.1 months, as detected with clonoSEQ.
Read More
Blood Cancer TalksAcute Myeloid Leukemia | February 13, 2024
Dr. Patel and the hosts discuss the TRANSFORM-1 study, MANIFEST-2, AUGMENT-101, and more.
Leah SherwoodAcute Lymphoblastic Leukemia | January 31, 2024
The past two decades have witnessed a rapid change in the treatment of acute lymphoblastic leukemia.
Leah SherwoodAcute Lymphoblastic Leukemia | January 5, 2024
The approval is based on the clinical results from a single-arm, multicenter, pivotal study in China.
Melissa BadamoAcute Lymphoblastic Leukemia | December 4, 2023
The study determined the maximum tolerated dose of asciminib with dasatinib and prednisone.
Melissa BadamoAcute Lymphoblastic Leukemia | December 4, 2023
93% of patients became measurable residual disease (MRD) negative after the first cycle of blinatumomab.
Advertisement
Leah SherwoodAcute Lymphoblastic Leukemia | December 3, 2023
Adding blinatumomab to consolidation chemotherapy represents a new standard of care in newly diagnosed B-lineage ALL.
Melissa BadamoAcute Lymphoblastic Leukemia | November 13, 2023
After a follow-up of 24 months, the two-year relapse free survival was 54% and the two-year overall survival rate was 60%.
Melissa BadamoAcute Lymphoblastic Leukemia | November 13, 2023
The effect of elevated BMI was more pronounced in older adolescent and young adults (AYAs) compared to younger AYAs.
Cecilia BrownPrint | November 13, 2023
Dr. Tasian discusses the path that took her to the best job in the world, silver linings along the way, and more.
Melissa BadamoAcute Lymphoblastic Leukemia | November 6, 2023
The strategy is “potentially translatable to all T-cell derived hematological malignancies," according to researchers.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | October 19, 2023
Elias Jabbour, MD, discusses the most burning questions in acute lymphoblastic leukemia (ALL).
Cecilia BrownAcute Lymphoblastic Leukemia | October 3, 2023
The pooled ORR was 97% and the pooled complete remission rate was 93% in patients with ALL.
Cecilia BrownAcute Lymphoblastic Leukemia | October 2, 2023
The study included 255 patients aged one to 30 years with low-risk first-relapse B-ALL.
Cecilia BrownAcute Lymphoblastic Leukemia | February 8, 2024
Researchers conducted the study because the "optimal treatment strategy for these patients is still a matter of debate.”
Cecilia BrownAcute Lymphoblastic Leukemia | October 11, 2023
JZP458, which is approved in the United States and Canada, is a new Erwinia-derived asparaginase.
Cecilia BrownAcute Lymphoblastic Leukemia | September 20, 2023
Researchers retrospectively analyzed treatment outcomes of 69 patients with relapsed or refractory CRLF2-rearranged B-ALL.
Cecilia BrownAcute Lymphoblastic Leukemia | September 20, 2023
Low hypodiploidy “defines a rare subtype” of B-cell ALL with a “dismal outcome.”
Karun Neupane, MDVideo Insights | September 10, 2023
The single-center study was conducted to address gaps in knowledge surrounding minority-predominant populations of patients.
Elias Jabbour, MDAcute Lymphoblastic Leukemia | February 8, 2024
Dr. Jabbour presented data from the study at the Eleventh Annual Meeting of SOHO.
Advertisement
Advertisement
Editorial Board